-
2002
Catalyst Founded
Board of Directors formed.
-
2002
CPP-109, a GABA analog
In-licensed from Brookhaven National Laboratory for the treatment of cocaine and other addictions (development terminated in 2009).
-
2006
CPRX listed on NASDAQ
-
2009
CPP-115, a GABA aminotransferase (GABA-AT) inactivator
In-licensed from Northwestern University (development terminated 2018).
-
2012
FIRDAPSE® (amifampridine)
Secured North American rights from BioMarin.
-
2018
FIRDAPSE
Approved by the U.S. Food and Drug Administration (FDA) for symptoms of Lambert-Eaton Myasthenic Syndrome (LEMS). FIRDAPSE is the first evidence-based product approved by the US FDA for LEMS.
-
2019
FIRDAPSE
Catalyst and BioMarin agree to provide Catalyst with exclusive rights to FIRDAPSE in Japan and potential rights for parts of Asia and Central and South America.
-
2020
FIRDAPSE
Approved in Canada by Health Canada.
Sublicensed rights to Kye in Canada.
SERB SA acquired BioMarin’s overall license for FIRDAPSE and is Catalyst’s global licensor.
-
2021
FIRDAPSE
Sublicensed rights in Japan to DyDo Pharma.
-
2023
FYCOMPA® (perampanel)
Acquired US rights from Eisai.
-
2023
AGAMREE® (vamorolone)
Acquired North American rights from Santhera.
Received US FDA approval for DMD. -
2024
FIRDAPSE
Received approval in Japan.
-
2024
AGAMREE
Launched in the US.
Entered license agreement with Kye Pharmaceuticals in Canada. -
2025
AGAMREE
Approved in Canada by Health Canada–first product approved in Canada for DMD.
-
2025
FIRDAPSE
Commercially available in Japan.
“Empathy is embedded in who we are. It means we treat not only patients and families that way, but also each other, customers and everyone we come into direct contact with.”
—Tina Adams-Newbill, HR
